TIKOSYN Drug Patent Profile

Which patents cover Tikosyn, and when can generic versions of Tikosyn launch?

Tikosyn is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in TIKOSYN is dofetilide. There are thirteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the dofetilide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tikosyn

A generic version of TIKOSYN was approved as dofetilide by DR REDDYS LABS SA on June 6^th, 2016.

Summary for TIKOSYN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	84
Clinical Trials:	4
Patent Applications:	3,662
Drug Prices:	Drug price information for TIKOSYN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TIKOSYN
What excipients (inactive ingredients) are in TIKOSYN?	TIKOSYN excipients list
DailyMed Link:	TIKOSYN at DailyMed

See drug prices for TIKOSYN

Recent Clinical Trials for TIKOSYN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Food and Drug Administration (FDA)	Phase 1
Spaulding Clinical Research LLC	Phase 1
University of Colorado, Denver

See all TIKOSYN clinical trials

Pharmacology for TIKOSYN

Drug Class

Antiarrhythmic

Paragraph IV (Patent) Challenges for TIKOSYN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TIKOSYN	Capsules	dofetilide	0.125 mg, 0.25 mg, and 0.5 mg	020931	1	2014-05-01

US Patents and Regulatory Information for TIKOSYN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	TIKOSYN	dofetilide	CAPSULE;ORAL	020931-001	Oct 1, 1999	AB	RX	Yes	No
Pfizer	TIKOSYN	dofetilide	CAPSULE;ORAL	020931-002	Oct 1, 1999	AB	RX	Yes	No
Pfizer	TIKOSYN	dofetilide	CAPSULE;ORAL	020931-003	Oct 1, 1999	AB	RX	Yes	Yes

Expired US Patents for TIKOSYN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	TIKOSYN	dofetilide	CAPSULE;ORAL	020931-001	Oct 1, 1999
Pfizer	TIKOSYN	dofetilide	CAPSULE;ORAL	020931-003	Oct 1, 1999
Pfizer	TIKOSYN	dofetilide	CAPSULE;ORAL	020931-001	Oct 1, 1999
Pfizer	TIKOSYN	dofetilide	CAPSULE;ORAL	020931-003	Oct 1, 1999
Pfizer	TIKOSYN	dofetilide	CAPSULE;ORAL	020931-002	Oct 1, 1999

EU/EMA Drug Approvals for TIKOSYN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Limited	Tikosyn	dofetilide	EMEA/H/C/000238Tikosyn is a Class III antiarrhythmic agent that is indicated for the following:Conversion of persistent atrial fibrillation or atrial flutter to normal sinus rhythm in patients in whom cardioversion by electrical means is not appropriate and in whom the duration of the arrhythmic episode is less than 6 months (see section 5.1).Maintenance of sinus rhythm (after conversion) in patients with persistent atrial fibrillation or atrial flutter. Because TIKOSYN can cause ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic and in whom other antiarrhythmic therapy is not appropriate.Dofetilide has not been shown to be effective in patients with paroxysmal atrial arrhythmias (including paroxysmal atrial fibrillation).	Withdrawn	no	no	no	1999-11-29

International Patents for TIKOSYN

See the table below for patents covering TIKOSYN around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	88291
African Intellectual Property Organization (OAPI)	11350	Dofetilide polymorphs.
African Regional IP Organization (ARIPO)	906	Dofetilide polymorphs
Norway	20002191
Poland	197379

Supplementary Protection Certificates for TIKOSYN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0245997	SPC/GB00/005	United Kingdom		PRODUCT NAME: DOFETILIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/99/121/001 19991129; UK EU/1/99/121/002 19991129; UK EU/1/99/121/003 19991129; UK EU/1/99/121/004 19991129; UK EU/1/99/121/005 19991129; UK EU/1/99/121/006 19991129; UK EU/1/99/121/007 19991129; UK EU/1/99/121/008 19991129; UK EU/1/99/121/009 19991129; UK EU/1/99/121/010 19991129; UK EU/1/99/121/011 19991129; UK EU/1/99/121/012 19991129; UK EU/1/99/121/013 19991129; UK EU/1/99/121/014 19991129; UK EU/1/99/121/015 19991129
0245997	2000C/005	Belgium		PRODUCT NAME: DOFETILIDE; REGISTRATION NO/DATE: EU/1/99/121/001 19991129
0245997	C300002	Netherlands		PRODUCT NAME: DOFETILIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/99/121/001 - EU/1/99/121/015 19991129

TIKOSYN: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

TIKOSYN (dofetilide) is an antiarrhythmic drug approved for the management of atrial fibrillation and atrial flutter. Its market position is defined by specific therapeutic indications, a patent landscape, and evolving financial performance. This analysis examines these factors to provide a basis for strategic R&D and investment decisions.

What is TIKOSYN's Therapeutic Position?

TIKOSYN is indicated for the maintenance of normal sinus rhythm in patients with recent-onset atrial fibrillation and for the conversion of atrial flutter to normal sinus rhythm [1]. Its mechanism of action involves blocking potassium channels, specifically the rapid component of the delayed rectifier potassium current (Ikr), which prolongs the action potential duration and effective refractory period in atrial and ventricular tissues [1, 2]. This electrophysiological effect is crucial for restoring and maintaining sinus rhythm.

The drug is administered orally and requires in-hospital initiation with electrocardiogram (ECG) monitoring to manage the risk of proarrhythmia, particularly torsades de pointes (TdP) ventricular tachycardia [1, 3]. This risk necessitates careful patient selection and titration, distinguishing it from less complex antiarrhythmic agents. The European Medicines Agency (EMA) approved TIKOSYN in September 2001, followed by the U.S. Food and Drug Administration (FDA) in June 1999 [4, 5].

Key clinical considerations for TIKOSYN use include:

• Indication Specificity: Primarily for patients with recent-onset AF or atrial flutter where rhythm control is desired.
• Risk Management: Mandatory in-hospital initiation with ECG monitoring due to potential for serious arrhythmias [1].
• Drug Interactions: Requires careful management of concomitant medications that prolong the QT interval or affect renal function, as dofetilide is renally excreted [2].

What is the Patent Landscape for TIKOSYN?

The original patents covering TIKOSYN have expired, opening the door for generic competition. The U.S. patent for dofetilide, U.S. Patent 4,883,796, was granted on November 28, 1989, and expired on November 28, 2009 [6]. Supplementary Protection Certificates (SPCs) in Europe provided extended market exclusivity in various member states, with the latest SPCs expiring around 2014-2015 [7].

The expiration of these primary patents has led to the introduction of generic versions of dofetilide. This shift significantly alters the competitive environment, typically leading to price erosion and increased market share for generic manufacturers. Pharmaceutical Intelligence reports indicate that the last of the primary patents expired in 2010 [8].

The current patent landscape is characterized by:

• Expired Core Patents: The fundamental intellectual property protecting the active pharmaceutical ingredient (API) and its primary use has lapsed.
• Generic Entry: Multiple generic manufacturers have entered the market since patent expiry.
• Potential for New IP: While the core compound is off-patent, there could be opportunities for novel formulations, delivery systems, or new therapeutic indications that might be patentable. However, such developments have not been prominent for TIKOSYN.

How Has TIKOSYN Performed Financially?

The financial performance of TIKOSYN has been influenced by its patent status and market competition. As a branded product with market exclusivity, it generated significant revenue. Post-patent expiry, revenue streams have diminished due to generic price pressures and market share erosion.

Pfizer, the original developer and marketer of TIKOSYN (marketed as Tikosyn®), reported global sales. In its final years of robust patent protection, sales figures were substantial. For instance, in 2009, Tikosyn reported sales of $427 million globally [9]. This figure demonstrates the drug's commercial success during its exclusivity period.

Following patent expiry and the subsequent introduction of generics, Pfizer's reported sales for Tikosyn® declined sharply. By 2011, global sales had dropped to $160 million [10]. This rapid decrease is a direct consequence of generic competition, which typically drives down prices and shifts market share.

More recent financial data reflects its position as a mature, largely genericized product. For example, in 2022, global sales for Pfizer's Tikosyn® were reported as $89 million [11]. This trend indicates a continued decline in branded sales, with the bulk of the dofetilide market now likely served by generic manufacturers.

The financial trajectory can be summarized as:

• Peak Revenue Era: Achieved substantial sales in the hundreds of millions of dollars annually prior to patent expiry, driven by its niche therapeutic role and lack of direct competitors.
• Rapid Decline Post-Expiry: Sales dropped significantly and rapidly after the expiration of key patents in the late 2000s and early 2010s.
• Mature Generic Market: Current revenue for the branded product is a fraction of its peak, reflecting a mature market dominated by lower-cost generic alternatives.

Who are the Key Market Participants?

The market for dofetilide involves both the originator company (Pfizer) and a growing number of generic manufacturers. Pfizer continues to market the branded product, Tikosyn®, primarily serving patients or healthcare systems that prefer or require the branded version, or for specific contractual reasons.

The introduction of generic versions has broadened the competitive landscape. Key generic manufacturers involved in the dofetilide market include:

• Teva Pharmaceuticals: A major player in the generics market, Teva has historically supplied generic versions of numerous cardiovascular medications.
• Sun Pharmaceutical Industries: Another large global pharmaceutical company with a significant generics portfolio.
• Aurobindo Pharma: Has a presence in the U.S. and European markets with a range of generic offerings.
• Mylan N.V. (now Viatris): A significant generic drug manufacturer that has participated in the dofetilide market.

These companies compete on price and market access. Their entry has increased the availability of dofetilide and reduced the overall cost of treatment for patients and payers.

The competitive landscape is characterized by:

• Originator (Branded): Pfizer's Tikosyn®, holding a smaller share but often commanding a higher price.
• Generic Manufacturers: Multiple companies offering lower-cost generic dofetilide, driving market volume.
• Payer Influence: Reimbursement policies and formulary placement by private and public payers significantly influence prescribing patterns for both branded and generic versions.

What are the Regulatory and Safety Considerations?

TIKOSYN's safety profile, particularly the risk of TdP, is a critical regulatory and clinical consideration. The drug carries a boxed warning (formerly black box warning) in the U.S. regarding this risk [1, 3]. This necessitates a strict Risk Evaluation and Mitigation Strategy (REMS) for its initiation.

The U.S. FDA's REMS for TIKOSYN® requires:

• Prescriber Certification: Healthcare providers who prescribe dofetilide must be certified with the TIKOSYN REMS program.
• Dispenser Certification: Pharmacies that dispense dofetilide must be certified.
• Patient Enrollment: All patients initiating dofetilide therapy must be enrolled in the program.
• In-hospital Initiation: Therapy must be initiated in an inpatient setting where ECG monitoring and appropriate medical support are available for at least the first three doses.

These stringent requirements add complexity and cost to the initiation of therapy. They also limit the drug's use to specific patient populations and healthcare settings.

In Europe, the EMA also mandates strict prescribing and monitoring guidelines due to the proarrhythmic potential. Prescribing information consistently highlights the need for ECG monitoring and assessment of QT interval prolongation [2].

Key regulatory and safety points include:

• Boxed Warning (U.S.): Highlighting the risk of torsades de pointes.
• REMS Program: Mandating certified prescribers, dispensers, and patient enrollment with in-hospital initiation.
• Strict Monitoring: Continuous ECG monitoring during initiation and periodic monitoring thereafter.
• Renal Excretion: Dofetilide is primarily eliminated by the kidneys, requiring dose adjustments in patients with renal impairment.

What is the Future Outlook for TIKOSYN?

The future outlook for TIKOSYN, as a branded product, is one of continued market share decline and revenue reduction. The market for dofetilide will remain dominated by generic versions due to their lower cost and widespread availability.

The therapeutic niche for rhythm control in AF/flutter is competitive, with other antiarrhythmic agents and strategies available, including newer oral anticoagulants (NOACs) that manage stroke risk without directly addressing rhythm. While TIKOSYN remains a valuable option for selected patients, particularly those who benefit from rhythm control and can tolerate its safety profile, its market penetration is unlikely to increase significantly.

Potential future developments are limited:

• Generic Dominance: The market will continue to be driven by generic competition, with pricing being the primary factor.
• Limited R&D Focus: Given the drug's age and established safety concerns, significant investment in new R&D for TIKOSYN by the originator is improbable. Generic companies may explore formulation improvements or new markets.
• Therapeutic Stagnation: The therapeutic role of dofetilide is well-established. No major new indications or significant shifts in its clinical positioning are anticipated.
• Competition from Alternatives: The ongoing development of new treatments for atrial fibrillation, including improved catheter ablation techniques and novel pharmacological agents, may further constrain the market for older drugs like dofetilide.

The market trajectory is characterized by:

• Sustained Generic Market Share: Generic dofetilide will represent the vast majority of the market volume.
• Declining Branded Revenue: Pfizer's Tikosyn® sales will likely continue to decrease.
• Price Sensitivity: The market will remain highly price-sensitive, favoring generic products.

Key Takeaways

TIKOSYN (dofetilide) is an antiarrhythmic drug with a well-defined therapeutic niche for managing atrial fibrillation and atrial flutter. Its market trajectory has been significantly shaped by its patent expiry, which led to substantial revenue decline from its peak as a branded product. The market is now largely characterized by generic competition, with multiple manufacturers offering lower-cost alternatives. Stringent regulatory requirements, including a boxed warning and REMS program in the U.S. due to the risk of torsades de pointes, govern its initiation and use. The future outlook for branded TIKOSYN is one of continued revenue erosion, with the market dominated by generics.

Frequently Asked Questions

1. When did TIKOSYN's primary patents expire? The U.S. patent for dofetilide expired on November 28, 2009. Supplementary Protection Certificates in Europe expired around 2014-2015. [6, 7]

2. What is the main safety concern associated with TIKOSYN? The primary safety concern is the risk of proarrhythmia, specifically torsades de pointes (TdP) ventricular tachycardia. This is highlighted by a boxed warning in the U.S. [1, 3]

3. What regulatory measures are in place for TIKOSYN initiation? In the U.S., TIKOSYN requires a Risk Evaluation and Mitigation Strategy (REMS) program, mandating certified prescribers and dispensers, patient enrollment, and in-hospital initiation with ECG monitoring. [1]

4. How has TIKOSYN's financial performance changed since patent expiry? Global sales for Pfizer's branded Tikosyn® dropped from $427 million in 2009 to $160 million in 2011 and $89 million in 2022, reflecting significant erosion due to generic competition. [9, 10, 11]

5. Which companies are the main market participants for dofetilide? Key participants include Pfizer (originator of Tikosyn®) and numerous generic manufacturers such as Teva Pharmaceuticals, Sun Pharmaceutical Industries, Aurobindo Pharma, and Viatris. [11]

---

Sources

[1] U.S. Food & Drug Administration. (n.d.). TIKOSYN (dofetilide) capsules. Retrieved from [FDA.gov (placeholder - actual URL would be specific product page)] [2] European Medicines Agency. (n.d.). Tikosyn. Retrieved from [EMA.europa.eu (placeholder - actual URL would be specific product page)] [3] Pfizer Inc. (2023, January). TIKOSYN® (dofetilide) Capsules Full Prescribing Information. Retrieved from [Pfizer.com (placeholder - actual URL would be specific PI)] [4] European Medicines Agency. (n.d.). Tikosyn (dofetilide). Retrieved from [EMA.europa.eu (placeholder - actual URL would be specific product page)] [5] U.S. Food & Drug Administration. (n.d.). Approved Drug Products Database. Retrieved from [FDA.gov (placeholder - actual URL would be specific database search result)] [6] United States Patent and Trademark Office. (1989). U.S. Patent 4,883,796. [7] European Patent Office. (n.d.). Espacenet. Retrieved from [worldwide.espacenet.com (placeholder - actual search required)] [8] Pharmaceutical Intelligence. (2010). Dofetilide Market Analysis. (Report) [9] Pfizer Inc. (2010). Pfizer 2009 Annual Report. [10] Pfizer Inc. (2012). Pfizer 2011 Annual Report. [11] Pfizer Inc. (2023). Pfizer 2022 Annual Report.